Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product ...
Vertex Pharmaceuticals Incorporated today announced business and program updates ahead of upcoming investor meetings in January, including the company's scheduled webcast from the 44th annual J.P.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback